Raman Bhakhri
Optometrist · Chicago, ILNPI 1437446333
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Regeneron at 42.3% of the total. Reporting peaked in 2024 at $3,043 and has fallen 85.5% since, to $441 in 2025. Among optometrist clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 34 payments — averaging $190.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$3K
- Optos, Inc.$2K
- Apellis Pharmaceuticals, Inc.$1K
- Coopervision Inc.$425
- Johnson & Johnson Vision Care, Inc.$144
- Dompe US, Inc.$138
- plus $352 from 7 others
Across 4 payments — averaging $1602.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$6K
What the payments were for
- Consulting fees$3,54755%
- Speaking & faculty fees$1,50023%
- Food & beverage$1,41322%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 8 | $2,741 |
| Optos, Inc. | 1 | $1,500 |
| Apellis Pharmaceuticals, Inc. | 1 | $1,179 |
| Coopervision Inc. | 12 | $425 |
| Johnson & Johnson Vision Care, Inc. | 1 | $144 |
| Dompe US, Inc. | 2 | $138 |
| Astellas Pharma US Inc | 1 | $135 |
| Astellas Pharma Global Development | 1 | $67 |
| AbbVie | 2 | $41 |
| Alcon | 2 | $38 |
| Thea Pharma Inc. | 1 | $27 |
| Bausch & Lomb Americas Inc. | 1 | $25 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$2,659
- PANORAMIC OPHTHALMOSCOPE$1,500
- Acuvue$144
- Izervay$135
- Oxervate$110
How this compares
$6,479 in reported general payments places this provider in the 95th percentile of 2,257 optometrist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Brimonidine Tartrate | 16 | $715 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $484 |
| Latanoprost | 41 | $437 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Chicago
- Pamela LoweChicago$447K
- Michael ChaglasianChicago$367K
- Jessilin QuintChicago$366K
- Jullian CerasuoloChicago$329K
- Jennifer HarthanChicago$84K
- Neil HodurChicago$67K
- James SementilliChicago$25K
- Lindsay SicksChicago$23K
- Emma LoyfmanChicago$23K
- Michelle ManChicago$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.